ADCC, by triggering FCγRIII on NK cells, is the key mechanism that therapeutic antibodies utilize to act against tumors.5 To examine whether tumor regression induced by HER2-DC1 i.t. in combination with anti-HER2 antibodies treatment also require ADCC activity, we used FcγR-deficient (FcγRI/III-KO) mice model. Here, ZDHHC4 is linked to neoplasm.